[ad_1]
The World Health Organization (WHO) has finalized a report on the fight against antimicrobial resistance (AMR), stressing the urgency to act.
The final report – developed by the Interagency Coordination Group on Antimicrobial Resistance (IACG) – identifies 14 recommendations focused on the urgency and actions needed for a global fight against antimicrobial resistance.
"The challenges of antimicrobial resistance are complex and multifaceted, but they are not insurmountable," said WHO, highlighting the report's recommendations "to save millions of lives, preserve economic gains and more in the area of development, and to protect the future of drug-resistant diseases. "
The problems the report seeks to address are related to factors such as misuse and overuse of antimicrobial agents, poor prescribing practices, as well as weak regulation and surveillance.
At least 700,000 deaths are attributed each year to drug-resistant diseases, according to the report.
The report focuses on accelerating progress and innovation to protect the future of drug-resistant diseases, as well as collaboration for more effective action and increasing investments. The report also stresses strengthening accountability and global governance.
Each recommendation provides an overview of its purpose and considerations. Among the emergencies, national surveillance, regulatory frameworks and enforcement capabilities need to be improved in all countries. This involves investing additional resources to accelerate regulatory approvals, monitor AMR and support access to antimicrobials, affordability and appropriate use. "Harmonized regulatory guidelines for new antimicrobials, vaccines and antimicrobial alternatives (…) will help avoid registration and commercialization issues related to divergent requirements and approval processes," notes the Consultative Committee.
IACG also recommends "the urgent establishment of a One Health Global Leadership Group" on antimicrobial resistance, despite opposition to the US government's response to draft recommendations. An "essential first step" is to immediately stop the use of antimicrobials in WHO's list of high priority antimicrobials, such as quinolones, as growth factors.
Members of the World Health Assembly adopted the Antimicrobial Resistance Plan in 2015. In recent years, several regulatory authorities have decided to develop their own plans. These include the European Medicines Agency and the US Food and Drug Administration, which are seeking reimbursement reforms.
A report published by the WHO in 2018 showed great disparities in the use of antibiotics between different countries. He cited the overuse and misuse of antibiotics as the main causes of AMR. "The findings of this report confirm the need for urgent action, such as the implementation of prescription-only policies, to reduce the unnecessary use of antibiotics," said Suzanne Hill. Director of the WHO Department of Essential Drugs and Health Products.
WHO
Source link
